Sinemet and Rash papular - a phase IV clinical study of FDA data

Summary:

Rash papular is reported as a side effect among people who take Sinemet (carbidopa; levodopa), especially for people who are female, 60+ old, also take Synthroid, and have Pain.

The phase IV clinical study analyzes which people have Rash papular when taking Sinemet. It is created by eHealthMe based on reports of 28,351 people who have side effects when taking Sinemet from the FDA, and is updated regularly.

What is Sinemet?

Sinemet has active ingredients of carbidopa; levodopa. It is often used in parkinson's disease. eHealthMe is studying from 29,601 Sinemet users. Check the latest studies of Sinemet.

What is Rash papular?

Rash papular (redness with papule) is found to be associated with 1,126 drugs and 1,329 conditions by eHealthMe. Check the latest studies of Rash papular.

On Jul, 29, 2026

28,351 people reported to have side effects when taking Sinemet.
Among them, 17 people (0.06%) have Rash papular.

Among these 17 people:

What is the gender of people who have Rash papular when taking Sinemet? *

female: 52.94 %
male: 47.06 %

What is the age of people who have Rash papular when taking Sinemet? *

What are other drugs people take besides Sinemet? *

Magnevist: 8 people, 47.06%
Omniscan: 8 people, 47.06%
Renagel: 8 people, 47.06%
Coumadin: 8 people, 47.06%
Synthroid: 8 people, 47.06%
Neurontin: 5 people, 29.41%
Sulfasalazine: 5 people, 29.41%
Prohance: 5 people, 29.41%
Midodrine Hydrochloride: 5 people, 29.41%
Multihance: 5 people, 29.41%

What are other side effects people have besides Rash papular? *

Weakness: 12 people, 70.59%
Itching: 11 people, 64.71%
Rashes (redness): 11 people, 64.71%
Joint Pain: 9 people, 52.94%
Gait Disturbance: 9 people, 52.94%
Skin Hypertrophy (skin cells enlarges): 8 people, 47.06%
Nephrogenic Systemic Fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease): 8 people, 47.06%
Hyperkeratosis (thickening of the outer layer of the skin): 8 people, 47.06%
Mobility Decreased (ability to move is reduced): 8 people, 47.06%
Skin Induration (an abnormally hard spot or area on the skin): 7 people, 41.18%

What are the existing conditions these people have? *

Pain: 7 people, 41.18%
Nuclear Magnetic Resonance Imaging Brain: 5 people, 29.41%
Anaemia (lack of blood): 3 people, 17.65%
Bronchospasm (spasm of bronchial smooth muscle producing narrowing of the bronchi): 3 people, 17.65%
Polymyalgia Rheumatica (pain in many muscles): 3 people, 17.65%
Depression: 3 people, 17.65%
Stress And Anxiety: 2 people, 11.76%
Dyspnea (difficult or laboured breathing): 2 people, 11.76%
High Blood Pressure: 2 people, 11.76%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 11.76%

* Approximation only. Some reports may have incomplete information.

Do you take Sinemet and have Rash papular?

- Check whether Rash papular is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sinemet:

Sinemet (29,601 reports)

Rash papular treatments and more:

Rash papular (25,753 reports)

Browse all side effects of Sinemet:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rash papular:

Rash papular (1,126 drugs)

Browse all the conditions that are associated with Rash papular:

Rash papular (1,329 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on carbidopa; levodopa (the active ingredients of Sinemet) and Sinemet (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.